Nirmidas Has Obtained 12-Month Shelf Life for MidaSpot® COVID-19 Antibody Combo Detection Kit

2021-11-09

To comply with regular shelf-life testing updates imposed by the FDA for MidaSpot® COVID-19 Antibody Combo Detection Kit to be maintained as an Emergency Use Authorization (EUA) product, the following lots have been extended until the new dates as shown below: Kit Lot NumberTest Card Lot NumberNew Expiration Date15933159322022.01.1716203162012022.01.3016401163992022.08.15 The FDA letter can be vi

MORE>

Nirmidas Biotech Receives FDA Emergency Use Authorization for its COVID-19 Rapid Antibody Fingerstick Test

2021-01-05

Click Here for News on Businesswire Click Here for News on 360 DXLearn More about MidaSpot COVID-19 Antibody Combo Detection Kit How to Purchase MdiaSpot COVID-19 Antibody Combo Detection Kit

MORE>

Nirmdas Has Developed High-Accuracy pGOLD™ Microarray Based High Throughput ELISA-like COVID-19 IgG/IgM/IgA Assay for Research Use Only

2020-04-06

Nirmidas Biotech Inc. announces the availability of pGOLD™ COVID-19 IgG/IgM or IgG/IgM/IgA Assay kits for simultaneous, multiplexed detection of IgG, IgM and IgA antibodies against COVID-19, each assay requiring only 1 micro-liter of patient sera, plasma or whole blood (fresh or from dried spots on blood cards). This assay is initially for research use only. It will be eligible for LDT tests in clinical labs upon implementations.

MORE>

Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations

Messenger RNA (mRNA) based vaccines (Pfizer/BioNTech and Moderna) are highly effective at providing immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is uncertainty about the duration of immunity, evolution of IgG antibody levels and IgG avidity (an index of antibody-antigen binding strength), and differences in the immune responses between vaccines.

A New Saliva-Based Lateral-Flow SARS-CoV-2 IgG Antibody Test for mRNA Vaccination

Sensitive detection of IgG antibodies against SARS-CoV-2 is important to assessing immune responses to viral infection or vaccination and immunity duration. Antibody assays using non-invasive body fluids such as saliva could facilitate mass testing including young children, elderly and those who resist blood draws, and easily allowing longitudinal testing/monitoring of antibodies over time.

Comparison of Anti-Dengue and Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing

Antibody cross-reactivity confounds testing for dengue virus (DENV) and Zika virus (ZIKV). We evaluated anti-DENV and anti-ZIKV IgG detection using a multiplex serological platform (the pGOLD assay) in patients from the Asunción metropolitan area in Paraguay, which experiences annual DENV outbreaks but has reported few autochthonous ZIKV infections.